BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Diabetes mellitus
,
Embryo
,
Anticancer prodrugs
,
Trichostatin A
,
rs2230926
,
VEGFA
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
nsc 652287
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
ATF3
ABCF2
JUN
BTG2
GPHN
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
DACOSTA_UV_RESPONSE_VIA_ERCC3_DN
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN
GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN
MARTINEZ_RESPONSE_TO_TRABECTEDIN
DAZARD_RESPONSE_TO_UV_NHEK_DN
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
p53-reactivating drug RITA treated HCT116 wildtype and TP53 null cells
Explore Curated Studies Results
Literature
Most Relevant Literature
Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor …
Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and…
Effect of RITA on TP53 Mutant Human Mantle Cell Lymphoma Cell Line and Its Mechanism].
Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells …
RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells].
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for nsc 652287
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ